XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Research, Collaboration and Licensing Agreements - Schedule of Revenue Recognized from Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2025
Jan. 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     $ 27,110 $ 10,030
Development support payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     0 168
Jazz: | Development support payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     4,493 2,066
Jazz: | Drug supply for ongoing studies        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     2,957 6,218
Jazz: | Other drug supply        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     2,150 1,578
Jazz: | Royalties        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     202 0
BeiGene, Ltd. (“BeiGene”): | Other drug supply        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue     208 0
GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”): | Milestone revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   $ 14,000 14,000 0
Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”): | Milestone revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue $ 3,100   $ 3,100 $ 0